Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Globe Newswire•04/11/2026•07:30 ET
0
Key Highlights
- ➤Aetna agreement adds approximately 26 million medical members to CNSide’s contracted payer footprint
- ➤Cerenome now has in-network agreements representing approximately 190 million covered lives
- ➤Agreement covers CNSide tumor cell enumeration and molecular profiling tests
- ➤CNSide tests performed exceeded 11,000 since 2020 across more than 120 U.S. cancer institutions
Expert Statements
Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome
“This national agreement with Aetna represents a new and important milestone in CNSide’s commercial trajectory”
Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome
“By expanding contracted reimbursement to now include both tumor cell enumeration and molecular profiling, we intend to pursue similar arrangements across our entire payer base to secure a payment pathway for patients for the most critical diagnostic tests we offer.”
Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives
First national CNSide payer agreement to include both tumor cell enumeration and molecular profiling
Get started
Create a free account to read the full story.